'On consolidated basis
Quarter ended June 2025 compared with Quarter ended June 2024.
Net sales (including other operating income) of Cipla has increased 3.94% to Rs 6957.47 crore. Sales of Phamaceuticals segment has gone up 2.98% to Rs 6,579.42 crore (accounting for 93.68% of total sales). Sales of New Ventures segment has gone up 25.35% to Rs 443.70 crore (accounting for 6.32% of total sales). Inter-segment sales rose Rs 49.34 crore to Rs 65.65 crore.
Profit before interest, tax and other unallocable items (PBIT) has jumped 9.49% to Rs 1,783.98 crore. PBIT of Phamaceuticals segment rose 5.92% to Rs 1,727.22 crore (accounting for 96.82% of total PBIT). PBIT of New Ventures reported profit of Rs 56.76 crore compared to loss of Rs 1.33 crore.
PBIT margin of Phamaceuticals segment rose from 25.52% to 26.25%. PBIT margin of New Ventures segment rose from negati...
Pleaselogin & subscribe to view the full report.
More Reports
|
|